A lyophilized-product program should be assessed as a connected product-and-process system. The question is not only whether a site lists lyophilization, but whether the specific product can be developed, transferred or manufactured through an evidence-based route with responsibilities and acceptance criteria defined in advance.

1. Define the product and route before comparing facilities

Start with non-confidential facts: sterile dosage form, presentation, target market, development stage, intended scale, requested cooperation model and timing. Then identify the proposed route from solution preparation through filling, loading, lyophilization, stoppering, inspection, packaging and storage. This prevents an early comparison based only on a generic platform label.

2. Test product-to-cycle fit, not only equipment availability

Ask what evidence supports the cycle for the product or a scientifically relevant development pathway. The review should address formulation behavior, critical product attributes, loading configuration, shelf and chamber conditions, primary and secondary drying strategy, stoppering, scale effects, hold times and the analytical evidence used to assess the resulting cake and product quality. The purpose is not to request confidential process detail at first contact; it is to determine whether a staged technical assessment is warranted.

3. Assess sterile control as part of the lyophilized process

Lyophilization does not remove the need for a coherent sterile-manufacturing control strategy. WHO’s current sterile-product GMP text addresses contamination control as a comprehensive system across the pharmaceutical quality system, facilities, personnel, utilities, monitoring and lifecycle management. [1] FDA’s aseptic-processing guidance likewise addresses buildings, personnel, components, sterilization, media fills, environmental monitoring, laboratory controls and documentation. [2]

4. Review the evidence trail around the critical interfaces

  • Before the cycle: solution preparation, filtration strategy where applicable, component preparation, equipment cleaning and sterilization/depyrogenation controls.
  • During filling and loading: aseptic interventions, loading configuration, time limits, monitoring and response to deviations.
  • During and after the cycle: chamber performance, stoppering, unloading, container-closure strategy, inspection and product-specific stability linkage.
  • Across the lifecycle: validated methods, change control, deviations, CAPA, data review and the rationale for any scale or equipment change.

5. Treat technology transfer as a controlled project, not a document handoff

For a product moving between teams or sites, the transfer package should make clear what knowledge is transferred, which gaps are still open, how analytical and process evidence will be evaluated, who approves changes and what acceptance criteria govern each stage. WHO’s pharmaceutical technology-transfer guideline is a useful public reference for the project-governance questions that must be resolved. [3]

6. Use a staged due-diligence sequence

Stage 1Non-confidential screen

Confirm dosage form, presentation, market, stage, intended model and timing—without sending formulas, dossiers or sensitive materials.

Stage 2Mutual confidentiality

Agree an NDA and a controlled exchange process before reviewing confidential development, analytical or transfer information.

Stage 3Technical and quality fit

Evaluate product-route fit, cycle evidence, sterile controls, analytical package, target-market requirements and site-level responsibilities.

Stage 4Project definition

Define scope, change control, milestones, acceptance criteria, commercial assumptions and the responsible parties before commitment.

Frequently asked questions

What should be reviewed before selecting a CMO for lyophilized products?

Begin with the product and intended manufacturing route, then evaluate cycle-development evidence, sterile-process controls, container closure, analytical and stability package, transfer responsibilities and target-market requirements.

Does a listed lyophilized platform prove that a project can be accepted?

No. A public platform description supports initial screening only. Product-specific technical, quality, regulatory, capacity and commercial assessment is still required.

What information can be shared for an initial lyophilized CMO assessment?

Share non-confidential facts such as dosage form, presentation, target market, development stage, intended cooperation model and timing. Do not send formulas, dossiers, patient information or controlled materials before an agreed confidential-exchange process.

Authoritative sources

  1. WHO TRS 1044, Annex 2 — Good manufacturing practices for sterile pharmaceutical products
  2. U.S. FDA — Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice
  3. WHO TRS 1044, Annex 4 — Guidelines on technology transfer in pharmaceutical manufacturing

This article is an industry perspective for general business discussion. It is not legal, regulatory or medical advice. Project requirements must be confirmed with the responsible parties and applicable authorities.